Annovis Bio CFO Henry Hagopian resigns; CEO Maria Maccecchini named interim CFO

Annovis Bio, Inc.

Henry Hagopian stepped down as CFO effective April 30, 2024, to pursue other opportunities; no disagreement with company.
CEO Maria Maccecchini appointed as interim principal financial officer effective May 1, 2024.
Severance includes 2 months base salary ($62,500) plus $3,000 medical/dental reimbursement, paid as lump sum.
Company accelerates vesting of 10,000 stock options and extends exercise period for certain options through Dec 31, 2024.
Hagopian signed a separation agreement with a general release of claims and non-disparagement obligations.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Maria Maccecchini

interim principal financial officer

ANVS · Annovis Bio, Inc.

Effective: 2024-05-01
Filed: May 1, 2024, 7:59 PM ET

On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.

Departed

Henry Hagopian

Chief Financial Officer

ANVS · Annovis Bio, Inc.

Effective: 2024-04-30
Successor: Maria Maccecchini
Filed: May 1, 2024, 7:59 PM ET

Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Maria Maccecchini was appointed as interim principal financial officer at Annovis Bio, Inc..

Action: appointed
Role: interim principal financial officer

Exact text from the filing

On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Henry Hagopian departed as Chief Financial Officer at Annovis Bio, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.

View on SEC.gov

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-055838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.